FDA and EMA grant orphan designations to FLAG-003 for glioma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA and the European Medicines Agency have both granted Orphan Drug Designation to FLAG-003 for the treatment of glioma, sponsored by FLAG Therapeutics. Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases, those which affect fewer than 200,000 Americans annually. Orphan drug...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login